Form 4: Edgewise Therapeutics Director Jonathan Root Granted 30,000 Stock Options

Edgewise Therapeutics, Inc. Director Jonathan D. Root has been granted 30,000 stock options with an exercise price of $14.68, set to vest by mid-2026.

Summary

• Jonathan D. Root, a Director of Edgewise Therapeutics, Inc. (EWTX), was granted 30,000 stock options.
• The transaction date for the option grant was June 16, 2025.
• The exercise price for these stock options is $14.68 per share.
• The options will become 100% vested on the earlier of June 16, 2026, or the business day prior to the 2026 annual meeting of stockholders.
• The expiration date for these stock options is June 16, 2035.
• Following this transaction, Jonathan D. Root beneficially owns 30,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options to a director aligns their interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational or financial news.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued commitment and performance from the director over the next year.

Future Outlook

The granted stock options are subject to a vesting schedule, with full vesting expected by mid-2026, either on June 16, 2026, or prior to the 2026 annual meeting of stockholders. The options have a long-term expiration date of June 16, 2035, providing a significant window for potential exercise.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the grant of stock options to a director as part of their compensation package. Such grants are common practice in the biotechnology and pharmaceutical industries, including for companies like Edgewise Therapeutics, to attract and retain talent and align executive and director interests with shareholder value creation.

Corporate Governance

Related Party Transactions

• The grant of 30,000 stock options to Jonathan D. Root, a Director of Edgewise Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as positive, as it aligns the director's financial incentives with the company's stock performance, potentially leading to better long-term value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest on the earlier of June 16, 2026, or the business day prior to the 2026 annual meeting of stockholders.

Key Dates

Keywords

Edgewise Therapeutics, EWTX, Stock Options, Insider Transaction, Form 4, Director Compensation, Beneficial Ownership, Equity Grant